GlassScriptPhysician profile
Nguyen Waterman
NPI 1528098415
$3,604.90
in general payments reported to CMS, 2019-2025
20 companies · $1,118 in 2025
The $1,118 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.28 · 2020: $43.51 · 2021: $391 · 2022: $189 · 2023: $741 · 2024: $1,105 · 2025: $1,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,964.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $916.33 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $610.99 | 2022-2025 | Precision 1, Total30, Eysuvis |
| Bausch & Lomb Americas INC. | $477.37 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $310.93 | 2021 | |
| Sun Pharmaceutical Industries INC. | $278.69 | 2019-2025 | Cequa |
| Johnson & Johnson Vision Care, INC. | $245.79 | 2024 | |
| Oyster Point Pharma, INC. | $230.86 | 2023-2025 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $158.61 | 2022-2023 | |
| Dompe US, INC. | $95.30 | 2024-2025 | Oxervate |
| Allergan, INC. | $42.46 | 2021 | |
| Kala Pharmaceuticals, INC. | $41.39 | 2021-2022 | |
| Astellas Pharma US INC | $34.77 | 2024 | Izervay |
| Harrow Eye, LLC | $27.23 | 2024 | Vevye |
| Genentech USA, INC. | $26.29 | 2024 | Vabysmo |
| Biotissue Holdings INC. | $21.66 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $21.05 | 2024 | Tecnis Iol |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Apellis Pharmaceuticals, INC. | $16.97 | 2025 | Syfovre |
| Horizon Therapeutics Plc | $16.34 | 2023 | Tepezza |
| Sight Sciences, INC. | $12.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nguyen Waterman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.